Generated by AI
Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for neuropsychiatric disorders. Alto Neuroscience applies its Precision Psychiatry Platform to analyze brain biomarkers, EEG activity, neurocognitive assessments, wearable data, and other patient-specific measures to help match therapies with the people most likely to benefit. Its current pipeline includes drug candidates targeting bipolar depression, major depressive disorder, treatment-resistant depression, schizophrenia, and related cognitive and mood disorders. The company is centered on personalized psychiatry, using biology-driven research to support the development of novel psychiatric treatments. Alto Neuroscience is headquartered in Mountain View, California, and its work today is concentrated on advancing clinical-stage programs for mental health conditions through biomarker-guided drug development.
Website650 Castro Street
Mountain View, CA, 94041
United States
The latest articles about ANRO.
Here is how UnitedHealth Group (UNH) and Alto Neuroscience, Inc. (ANRO) have performed compared to their sector so far this year.
Summary of Apr 2's posts. Generated by AI.
Summary of Oct 20's posts. Generated by AI.
No summary yet.
Summary of Oct 24's posts. Generated by AI.
Investors talking about ANRO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.